The outcomes of patients with myocardial infarction(MI)have substantially improved given the rapid progress that has occurred in revascularization techniques and secondary prevention,and the majority of MI patients su...The outcomes of patients with myocardial infarction(MI)have substantially improved given the rapid progress that has occurred in revascularization techniques and secondary prevention,and the majority of MI patients subsequently enter a chronic stable phase.Therefore,the long-term management of patients with MI has become a core issue in daily clinical practice for cardiologists.The long-term incidence of adverse events can be further reduced using newly developed medications and therapies ranging from lipid-lowering agents(eg,proprotein convertase subtilisin/kexin type 9 inhibitors)to anti-thrombotic treatments(eg,shortened dual anti-platelet therapy).However,a considerable number of patients still experience adverse events,as some residual risk can remain despite intensive secondary prevention,such as continuously elevated cholesterol levels,chronic cardiovascular inflammation,and rapid atherosclerosis progression due to increased plaque instability.Therefore,the present review sought to summarize and discuss recent advances in several key aspects regarding the long-term management of MI patients,with the expectation of clarifying the available treatment strategies for various clinical scenarios,examining the gaps between trial evidence and clinical practice,and providing possible directions for future research.展开更多
基金supported by the National Natural Science Foundation of China(81970308)the Fund of the“Sanming”Project of Medicine in Shenzhen(SZSM201911017)+1 种基金the Shenzhen Key Medical Discipline Construction Fund(SZXK001)the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2016-I2M-1-009).
文摘The outcomes of patients with myocardial infarction(MI)have substantially improved given the rapid progress that has occurred in revascularization techniques and secondary prevention,and the majority of MI patients subsequently enter a chronic stable phase.Therefore,the long-term management of patients with MI has become a core issue in daily clinical practice for cardiologists.The long-term incidence of adverse events can be further reduced using newly developed medications and therapies ranging from lipid-lowering agents(eg,proprotein convertase subtilisin/kexin type 9 inhibitors)to anti-thrombotic treatments(eg,shortened dual anti-platelet therapy).However,a considerable number of patients still experience adverse events,as some residual risk can remain despite intensive secondary prevention,such as continuously elevated cholesterol levels,chronic cardiovascular inflammation,and rapid atherosclerosis progression due to increased plaque instability.Therefore,the present review sought to summarize and discuss recent advances in several key aspects regarding the long-term management of MI patients,with the expectation of clarifying the available treatment strategies for various clinical scenarios,examining the gaps between trial evidence and clinical practice,and providing possible directions for future research.
